Programme

Topics include:

• Current limitations of HCV therapy in co-infected people and rationale for expanding access to HCV drugs for co-infected people.
• HCV drug pipeline.
• Regulations on drug clinical development.
• Proposals/groundwork for broadening access: Research and development in HIV/HCV co-infection (interaction studies, when to launch treatment trials, EAP critieria).

See final meeting programme below.

Location: Sitges, Spain